Congenia - mitochondrial mPTP platform

Mitochondrial mPTP Platform

Congenia discovers and develops small-molecule compounds designed to target and modulate (activating or inhibiting) the activity of the permeability transition pore (PTP), mitochondrial target involved in cellular ageing, senescence and apoptosis.
Congenia's current lead candidate is being developed for the treatment of reperfusion injury in acute myocardial infarction; other indications are also under indications including neurodegenerative disorders are also being evaluated.

For more information on Congenia's scientific programmes visit us at